TABLE 1.
Demographic and clinical characteristics of the participants at baseline, n = 58
| Characteristic | Mean (±SD) or median (quartiles) | Frequency (%) | Min–Max |
|---|---|---|---|
| Gender | |||
| Male | 24 (41%) | ||
| Female | 34 (59%) | ||
| Age, years | 36.5 (11.8) | 16–65 | |
| Epilepsy classification | |||
| Focal | 49 (85%) | ||
| Generalized | 9 (16%) | ||
| Age at first seizure, years | 7 (2–16) | 0–55 | |
| Epilepsy etiology | |||
| Structural | 16 (27.6%) | ||
| Genetic | 7 (12.1%) | ||
| Infectious | 4 (6.9%) | ||
| Unknown | 31 (53.4%) | ||
| Years with epilepsy | 25.0 (11.9) | 7–58 | |
| Seizure frequency per week | 3.5 (1.5–14.1) | .1–351.8 | |
| Intellectual disability | 21 (36%) | ||
| VNS, previous or current | 24 (41%) | ||
| Employment | |||
| Paid employment | 13 (22%) | ||
| Occupationally disabled | 37 (64%) | ||
| Other | 8 (14%) | ||
| Total number of ASMs tried | 8.7 (4.1) | 3–23 | |
| ASMs at diet initiation | 2.1 (.9) | 0–4 | |
Note: Data are presented as mean (±SD) or median (quartiles) and Min–Max for continuous variables, and frequency (percentage) for discrete variables.
Abbreviations: ASM, antiseizure medication; Min–Max, minimum–maximum; VNS, vagus nerve stimulator.